Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

J. Bubley, Glenn; A. Carducci, Michael; L. Dahut, William; A. Dawson, Nancy; Daliani, Danai; A. Eisenberger, Mario; D. Figg, William; Freidlin, Boris; Halabi, Susan; R. Hudes, Gary; Hussain, Maha; Kaplan, Richard; E. Myers, Charles; Oh, William; P. Petrylak, Daniel; Reed, Eddie; J. Roth, Bruce; Sartor, Oliver; I. Scher, Howard; W. Simons, Jonathan; Sinibaldi, Vickie; J. Small, Eric; R. Smith, Matthew; L. Trump, Donald; T. Vollmer, Robin; Wilding, George

doi:10.1200/jco.1999.17.11.3461

Public

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Published in Journal of Clinical Oncology • Nov 1, 1999

Authors:

Glenn J. Bubley

Michael A. Carducci

William L. Dahut

Abstract

PURPOSE: Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic disease, changes in PSA will often antedate changes in bone scan. Furthermore, many but not all investigators have observed an association...

Subject

Medicine

Prostate cancer

Prostate-specific antigen

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!